Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Clene’s cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S. FDA data.

VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.

Interestingly, Smith is the first non-verbal individual and only the third person globally to receive a Neuralink Brain-Chip ...

Alchemab Therapeutics enters $415 million licensing agreement with Eli Lilly for ATLX-1282: Cambridge, UK Wednesday, May 7, 2025, 12:00 Hrs [IST] Alchemab Therapeutics (Alchemab), ...

Prilenia, Ferrer entered collaboration agreement for commercialization and co-development of pridopidine in Europe and other ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Privately-held Alchemab Therapeutics, a biotech that uses the power of human immune evolution to identify and develop ...